Foghorn Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Foghorn Therapeutics Reports 2024 Results, Highlights Clinical Progress and Pipeline Expansion
Foghorn Therapeutics' 2024 10-K filing highlights clinical progress with FHD-909, pipeline expansion targeting chromatin regulatory system, and strategic collaboration with Eli Lilly.
NASDAQ
10-K: Foghorn Therapeutics Inc. Files 10-K, Highlights Pipeline Progress and Strategic Collaboration
Foghorn Therapeutics Inc.'s 2023 10-K filing details its financial status, pipeline advancements, and strategic collaboration with Lilly, emphasizing its focus on chromatin regulatory system therapeutics.